Cisplatin based chemotherpay
Phase 3Small molecule
Cisplatin based chemotherpay is one of 16 small molecule programs targeting Oropharyngeal Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Oropharyngeal Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxol
TevaPhase 2
Beyfortus
BeiGenePhase 2
Paraplatin
AAvyxa
Phase 2
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 2
Fludara
SanofiPhase 1
Balstilimab
AAgenus Inc.
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Cisplatin based chemotherpay
TTata Memorial Centre
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTata Memorial Centre